About Heart Failure Drugs
The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast period. Based on the drug class the market can be segmented into Beta blockers, ARBs, and ACE inhibitors. Angiotensin II receptor blockers (ARB) are a group of pharmaceuticals that modify the renin-angiotensin system. The heart disease drugs market is experiencing growth in the ARBs segment because it reduces the risk of death caused by heart failure and minimizes the chance of hospitalization of people with heart failure.
Technavio’s analysts forecast the global heart failure drugs market to grow at a CAGR of 10.46% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global heart failure drugs market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of heart failure drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Heart Failure Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Amgen
• AstraZeneca
• Bayer
• Novartis
Other prominent vendors
• Gilead
• GlaxoSmithKline
• Pfizer
• Teva Pharmaceutical industries
Market driver
• Rising geriatric population
• For a full, detailed list, view our report
Market trend
• Investment inclination toward developing countries
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Threat of new entrants
• Market condition
PART 08: MARKET SEGMENTATION BY DRUG CLASS
• Segmentation by drug class
• Comparison by drug class
• Global beta blockers market
• Global ARBs market
• Global ACE inhibitors market
• Global others market
• Market opportunity by drug class
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Heart failure drugs market in Americas
• Heart failure drugs market in EMEA
• Heart failure drugs market in APAC
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Growing strategic alliances
• Investment inclination toward developing countries
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive landscape
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amgen
• AstraZeneca
• Bayer
• Novartis
PART 16: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: Heart function, before and after heart failure
Exhibit 02: Factors causing heart failure
Exhibit 03: Stages of heart failure
Exhibit 04: Major treatment options for various stages of heart failure
Exhibit 05: Global heart failure rate 2015
Exhibit 06: Parent market
Exhibit 07: Market characteristics
Exhibit 08: Market segments
Exhibit 09: Market definition: Inclusions and exclusions checklist
Exhibit 10: Market size 2017
Exhibit 11: Validation techniques employed for market sizing 2017
Exhibit 12: Global heart failure drugs market 2017-2022 ($ millions)
Exhibit 13: Global heart failure drugs market: Year-over-year growth 2018-2022 (%)
Exhibit 14: Five forces analysis 2017
Exhibit 15: Five forces analysis 2022
Exhibit 16: Bargaining power of buyers
Exhibit 17: Threat of new entrants
Exhibit 18: Market condition: Five forces 2017
Exhibit 19: Global heart failure drugs market by drug class 2017-2022 (%)
Exhibit 20: Comparison by drug class
Exhibit 21: Global beta blockers market 2017-2022 ($ millions)
Exhibit 22: Common beta blockers used for CVDs
Exhibit 23: Global beta blockers market: Year-over-year growth 2018-2022 (%)
Exhibit 24: Global ARBs market 2017-2022 ($ millions)
Exhibit 25: Global ARBs market: Year-over-year growth 2018-2022 (%)
Exhibit 26: Global ACE inhibitors market 2017-2022 ($ millions)
Exhibit 27: Adverse effects of ACE inhibitors
Exhibit 28: Global ACE inhibitors market: Year-over-year growth 2018-2022 (%)
Exhibit 29: Global others market 2017-2022 ($ millions)
Exhibit 30: Global others market: Year-over-year growth 2018-2022 (%)
Exhibit 31: Market opportunity by drug class
Exhibit 32: Customer landscape
Exhibit 33: Global heart failure drugs market by geography 2017-2022 (%)
Exhibit 34: Regional comparison
Exhibit 35: Heart failure drugs market in Americas 2017-2022 ($ millions)
Exhibit 36: Heart failure drugs market in Americas: Year-over-year growth 2018-2022 (%)
Exhibit 37: Heart failure drugs market in EMEA 2017-2022 ($ millions)
Exhibit 38: Heart failure drugs market in EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 39: Heart failure drugs market in APAC 2017-2022 ($ millions)
Exhibit 40: Top Asian countries in terms of population with diabetes
Exhibit 41: Heart failure drugs market in APAC: Year-over-year growth 2018-2022 (%)
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: World population by age group 2015-2050 (millions)
Exhibit 45: Percentage of population aged 65 and above by region 2015 and 2050
Exhibit 46: Major complications of diabetes
Exhibit 47: Global obesity facts 2014
Exhibit 48: Percentage of workday spent walking or standing versus sitting in selected occupation 2016
Exhibit 49: Side effects of the drugs used in heart failure treatment and management
Exhibit 50: Demographic and economic snapshot of India and China
Exhibit 51: Vendor landscape
Exhibit 52: Landscape disruption
Exhibit 53: Competitive structure analysis of global heart failure drugs market
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors
Exhibit 57: Amgen: Vendor overview
Exhibit 58: Amgen: Business segments
Exhibit 59: Amgen: Organizational developments
Exhibit 60: Amgen: Geographic focus
Exhibit 61: Amgen: Segment focus
Exhibit 62: Amgen: Key offerings
Exhibit 63: AstraZeneca: Vendor overview
Exhibit 64: AstraZeneca: Business segments
Exhibit 65: AstraZeneca: Organizational developments
Exhibit 66: AstraZeneca: Geographic focus
Exhibit 67: AstraZeneca: Segment focus
Exhibit 68: AstraZeneca: Key offerings
Exhibit 69: Bayer: Vendor overview
Exhibit 70: Bayer: Business segments
Exhibit 71: Bayer: Organizational developments
Exhibit 72: Bayer: Geographic focus
Exhibit 73: Bayer: Segment focus
Exhibit 74: Bayer: Key offerings
Exhibit 75: Novartis: Vendor overview
Exhibit 76: Novartis: Business segments
Exhibit 77: Novartis: Organizational developments
Exhibit 78: Novartis: Geographic focus
Exhibit 79: Novartis: Segment focu
Exhibit 80: Novartis: Key offerings
